1800-272-662
Shopping Cart 0
countryflagAU
Login

Fate Therapeutics Inc

Healthcare US FATE

1.17USD
-0.06(4.88%)

Last update at 2026-03-12T20:18:00Z

Day Range

1.171.26
LowHigh

52 Week Range

1.638.83
LowHigh

Fundamentals

  • Previous Close 1.23
  • Market Cap402.97M
  • Volume1021049
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-181.17501M
  • Revenue TTM6.48M
  • Revenue Per Share TTM0.07
  • Gross Profit TTM -224.15400M
  • Diluted EPS TTM-1.93

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -281.72100M -212.15100M -173.38700M -98.14900M -66.59800M
Minority interest - - - - -
Net income -255.05600M -206.30100M -170.30000M -97.70800M -66.59800M
Selling general administrative 84.23M 57.32M 33.90M 23.64M 15.81M
Selling and marketing expenses - - - - -
Gross profit 96.30M 55.85M 31.43M 10.68M 4.74M
Reconciled depreciation 13.76M 5.85M 3.09M 2.19M 1.20M
Ebit -322.14400M -216.99400M -128.08500M -100.72700M -66.10600M
Ebitda -308.38600M -215.68500M -125.68500M -96.39700M -64.90200M
Depreciation and amortization 13.76M 1.31M 2.40M 4.33M 1.20M
Non operating income net other - 4.84M -45.30200M 2.58M 0.49M
Operating income -308.38600M -216.99400M -128.08500M -100.72700M -67.09200M
Other operating expenses 404.69M 272.84M 159.52M 111.41M 71.83M
Interest expense 5.84M 4.54M 2.40M 1.75M 1.70M
Tax provision - - - - -
Interest income 5.84M 1.31M 2.40M 4.33M 2.19M
Net interest income 5.84M 1.31M 2.40M 2.58M 0.49M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -26.66500M -5.85000M -3.08700M -0.44100M 2.19M
Total revenue 96.30M 55.85M 31.43M 10.68M 4.74M
Total operating expenses 404.69M 272.84M 159.52M 111.41M 71.83M
Cost of revenue - - - 87.77M 56.02M
Total other income expense net 26.66M 4.84M -45.30200M 2.58M 0.49M
Discontinued operations - - - - -
Net income from continuing ops -281.72100M -212.15100M -173.38700M -98.14900M -66.59800M
Net income applicable to common shares -281.72100M -212.15100M -173.38700M -98.14900M -66.59800M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 506.22M 705.56M 921.46M 622.46M 302.27M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 13.64M 27.37M 8.83M 5.89M 4.32M
Total liab 137.80M 221.62M 242.62M 238.01M 57.52M
Total stockholder equity 368.42M 483.94M 678.84M 384.44M 244.76M
Deferred long term liab - 7.20M 9.87M 13.51M 1.34M
Other current liab 27.51M 57.93M 45.61M 54.78M 17.50M
Common stock 0.10M 0.10M 0.10M 0.09M 0.08M
Capital stock 0.10M 0.10M 0.10M 0.09M 0.08M
Retained earnings -1211.73200M -1050.80400M -769.08300M -556.93200M -383.54500M
Other liab - 3.86M 52.09M 58.51M 4.48M
Good will - - - - -
Other assets 0.00000M 22.46M 25.13M 95.83M 1.57M
Cash 41.87M 61.33M 133.58M 167.35M 99.81M
Cash and equivalents - - - - -
Total current liabilities 39.09M 114.05M 81.28M 85.56M 27.81M
Current deferred revenue 0.69M 42.23M 21.48M 21.14M 2.79M
Net debt 61.67M 48.01M -18.76500M -70.04900M -72.88700M
Short term debt 6.18M 5.63M 5.58M 3.35M 1.69M
Short long term debt - - - - -
Short long term debt total 103.54M 109.34M 114.82M 97.30M 26.93M
Other stockholder equity 1580.03M 1536.50M 1448.58M 941.22M 628.20M
Property plant equipment - 176.09M 162.25M 32.31M 11.42M
Total current assets 331.54M 502.07M 633.41M 494.32M 227.09M
Long term investments 0.98M 4.94M 100.66M 0.00000M 39.44M
Net tangible assets - 483.94M 678.84M 536.89M 274.46M
Short term investments 273.31M 374.89M 482.33M 315.57M 121.61M
Net receivables 2.73M 38.48M 8.68M 5.51M 1.34M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 4.72M 8.27M 8.61M 6.28M 5.82M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.01M -1.85400M -0.76200M 0.07M 0.02M
Additional paid in capital - - - - -
Common stock total equity - - 0.10M 0.09M 0.08M
Preferred stock total equity - - 0.00300M 0.00300M 0.00300M
Retained earnings total equity - - -769.08300M -556.93200M -383.54500M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00900M 132.48M 116.66M 61.05M 12.99M
Deferred long term asset charges - - - - -
Non current assets total 174.68M 203.49M 288.04M 128.13M 75.19M
Capital lease obligations 103.54M 109.34M 114.82M 97.30M 26.93M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 166.75M -273.31900M -156.14400M -150.05800M 1.84M
Change to liabilities 14.25M 5.91M -1.55400M 4.28M 4.25M
Total cashflows from investing activities 166.75M -324.02300M -161.07600M -157.45300M -0.46300M
Net borrowings - - - -15.00000M -15.00000M
Total cash from financing activities 9.21M 453.13M 282.84M 149.93M 140.78M
Change to operating activities -19.15800M -0.64900M -5.70400M -1.13700M -2.01000M
Net income -281.72100M -212.15100M -173.38700M -98.14900M -66.59800M
Change in cash -72.25000M -33.76400M 82.53M -90.70000M 101.67M
Begin period cash flow 148.81M 182.57M 100.04M 190.74M 89.07M
End period cash flow 76.56M 148.81M 182.57M 100.04M 190.74M
Total cash from operating activities -248.20800M -162.87000M -39.22900M -83.17500M -38.65000M
Issuance of capital stock 0.00000M 411.74M 272.69M 162.41M 134.58M
Depreciation 13.76M 5.85M 3.09M 2.19M 1.20M
Other cashflows from investing activities - - - -150.05800M 1.84M
Dividends paid - - - -2.52200M -
Change to inventory - -5.90700M 1.55M -4.27700M -4.25400M
Change to account receivables -29.80400M -3.16000M -5.51500M 0.50M -0.50000M
Sale purchase of stock - 432.45M 248.41M 2.52M 2.69M
Other cashflows from financing activities 166.75M 41.39M 10.14M 2.52M 3.51M
Change to netincome 51.79M 37.34M 30.75M 17.41M 6.86M
Capital expenditures 35.57M 50.70M 4.93M 7.39M 2.30M
Change receivables - -3.16000M -5.51500M 0.50M -0.50000M
Cash flows other operating - -18.74700M 105.71M -9.04300M 16.39M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -33.76400M 82.53M -90.70000M 101.67M
Change in working capital -34.71000M 2.10M -12.77300M 3.64M 1.74M
Stock based compensation 78.73M 54.36M 30.75M 17.41M 6.29M
Other non cash items -24.26800M -18.09800M 111.42M -7.79100M 19.04M
Free cash flow -283.77400M -213.57400M -44.16100M -90.57000M -40.95300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
FATE
Fate Therapeutics Inc		 -0.06 4.88% 1.17 - - 10.33 1.78 7.02 -2.5897
NVO
Novo Nordisk A/S		 -0.81 2.09% 38.02 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 0.005 0.01% 38.70 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -14.25 2.89% 478.13 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -28.05 3.62% 746.61 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Fate Therapeutics Inc

12278 Scripps Summit Drive, San Diego, CA, United States, 92131

Key Executives

Name Title Year Born
Mr. J. Scott Wolchko Founder, CEO, Pres & Director 1970
Mr. Edward J. Dulac III Chief Financial Officer 1976
Dr. Mark Plavsic D.V.M., Ph.D. Chief Technical Officer 1961
Ms. Cindy R. Tahl Gen. Counsel & Corp. Sec. 1973
Dr. Bahram Valamehr Ph.D. Chief R&D Officer 1977
Dr. Yu-Waye Chu M.D. Chief Medical Officer NA
Mr. Jim Beitel M.B.A. Sr. VP of Corp. Devel. NA
Dr. Sarah Cooley Sr. VP of Clinical Translation NA
Dr. Jerome Bressi Ph.D. Sr. VP of Regulatory Affairs & Quality NA
Mr. Brian T. Powl M.B.A., M.S. Chief Commercial Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.